These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 30499732)

  • 61. Hormonally impregnated intrauterine systems (IUSs), versus other forms of reversible contraceptives as effective methods of preventing pregnancy.
    French R; Cowan F; Mansour D; Morris S; Hughes D; Robinson A; Proctor T; Summerbell C; Logan S; Guillebaud J
    Cochrane Database Syst Rev; 2001; (2):CD001776. PubMed ID: 11406007
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Changes in uptake and cost of long-acting reversible contraceptive devices following the introduction of a new low-cost levonorgestrel IUD in Utah's Title X clinics: a retrospective review.
    Roth LP; Sanders JN; Simmons RG; Bullock H; Jacobson E; Turok DK
    Contraception; 2018 Jul; 98(1):63-68. PubMed ID: 29574095
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Immediate postpartum intrauterine device and implant program outcomes: a prospective analysis.
    Eggebroten JL; Sanders JN; Turok DK
    Am J Obstet Gynecol; 2017 Jul; 217(1):51.e1-51.e7. PubMed ID: 28342716
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Canadian Contraception Consensus (Part 3 of 4): Chapter 7--Intrauterine Contraception.
    Black A; Guilbert E; Costescu D; Dunn S; Fisher W; Kives S; Mirosh M; Norman W; Pymar H; Reid R; Roy G; Varto H; Waddington A; Wagner MS; Whelan AM; Mansouri S
    J Obstet Gynaecol Can; 2016 Feb; 38(2):182-222. PubMed ID: 27032746
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Women's satisfaction with and ongoing use of hormonal long-acting methods compared to the oral contraceptive pill: Findings from an Australian general practice cluster randomised trial (ACCORd).
    Black KI; McGeechan K; Watson CJ; Lucke J; Taft A; McNamee K; Haas M; Peipert JF; Mazza D
    Aust N Z J Obstet Gynaecol; 2021 Jun; 61(3):448-453. PubMed ID: 33599984
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Preventing Unintended Pregnancy: The Contraceptive CHOICE Project in Review.
    Birgisson NE; Zhao Q; Secura GM; Madden T; Peipert JF
    J Womens Health (Larchmt); 2015 May; 24(5):349-53. PubMed ID: 25825986
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Sexual function and quality of life of women adopting the levonorgestrel-releasing intrauterine system (LNG-IUS 13.5 mg) after abortion for unintended pregnancy.
    Caruso S; Cianci S; Vitale SG; Fava V; Cutello S; Cianci A
    Eur J Contracept Reprod Health Care; 2018 Feb; 23(1):24-31. PubMed ID: 29436865
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Risk factors and the choice of long-acting reversible contraception following medical abortion: effect on subsequent induced abortion and unwanted pregnancy.
    Korjamo R; Heikinheimo O; Mentula M
    Eur J Contracept Reprod Health Care; 2018 Apr; 23(2):89-96. PubMed ID: 29537321
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Levonorgestrel Intrauterine Device Use in Overweight and Obese Women.
    Saito-Tom LY; Soon RA; Harris SC; Salcedo J; Kaneshiro BE
    Hawaii J Med Public Health; 2015 Nov; 74(11):369-74. PubMed ID: 26568900
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Not seeking yet trying long-acting reversible contraception: a 24-month randomized trial on continuation, unintended pregnancy and satisfaction.
    Hubacher D; Spector H; Monteith C; Chen PL
    Contraception; 2018 Jun; 97(6):524-532. PubMed ID: 29470950
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The Impact of Balanced Counseling on Contraceptive Method Choice and Determinants of Long Acting and Reversible Contraceptive Continuation in Nepal.
    Sapkota S; Rajbhandary R; Lohani S
    Matern Child Health J; 2017 Sep; 21(9):1713-1723. PubMed ID: 26955996
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Cost sharing, postpartum contraceptive use, and short interpregnancy interval rates among commercially insured women.
    Moniz MH; Peahl AF; Fendrick AM; Kolenic GE; Tilea A; Wetmore M; Dalton VK
    Am J Obstet Gynecol; 2021 Mar; 224(3):282.e1-282.e17. PubMed ID: 32898503
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Twelve-month discontinuation rates of levonorgestrel intrauterine system 13.5 mg and subdermal etonogestrel implant in women aged 18-44: A retrospective claims database analysis.
    Law A; Liao L; Lin J; Yaldo A; Lynen R
    Contraception; 2018 Apr; ():. PubMed ID: 29684326
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Uptake of the levonorgestrel intrauterine system among recent postpartum women in Kenya: factors associated with decision-making.
    Hubacher D; Masaba R; Manduku CK; Veena V
    Contraception; 2013 Jul; 88(1):97-102. PubMed ID: 23566383
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Low-income women and use of prescribed contraceptives in the context of full health insurance coverage in France, 2019.
    Congy J; Bouyer J; de La Rochebrochard E
    Contraception; 2023 May; 121():109976. PubMed ID: 36758736
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Predictors of contraceptive switching and discontinuation within the first 6 months of use among Highly Effective Reversible Contraceptive Initiative Salt Lake study participants.
    Simmons RG; Sanders JN; Geist C; Gawron L; Myers K; Turok DK
    Am J Obstet Gynecol; 2019 Apr; 220(4):376.e1-376.e12. PubMed ID: 30576664
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Hormonal and intrauterine methods for contraception for women aged 25 years and younger.
    Tang JH; Lopez LM; Mody S; Grimes DA
    Cochrane Database Syst Rev; 2012 Nov; 11():CD009805. PubMed ID: 23152281
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Acceptability of the levonorgestrel-releasing intrauterine system after discontinuation of previous contraception: results of a French clinical study in women aged 35 to 45 years.
    Dubuisson JB; Mugnier E
    Contraception; 2002 Aug; 66(2):121-8. PubMed ID: 12204786
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Acceptability of intrauterine contraception among women living with human immunodeficiency virus: a randomised clinical trial.
    Kakaire O; Tumwesigye NM; Byamugisha JK; Gemzell-Danielsson K
    Eur J Contracept Reprod Health Care; 2016 Jun; 21(3):220-6. PubMed ID: 26895345
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Long-acting reversible contraception methods in women under 26 years of age].
    Frutos-Balibrea I; Sánchez-Núñez MI; Pedrero-Pérez EJ; Haro-León A; Benítez-Robredo MT
    Semergen; 2021 Oct; 47(7):457-464. PubMed ID: 34148782
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.